Zealand Pharma Announces Financial Results for the Full Year 2023
27. Februar 2024 01:00 ET
|
Zealand Pharma
Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023 Significant progress delivered across our obesity and rare disease assets while building a...
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26. Februar 2024 02:06 ET
|
Zealand Pharma
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to...
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
20. Februar 2024 02:00 ET
|
Zealand Pharma
Press Release – No. 2 / 2024 Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results Copenhagen, Denmark, February 20, 2024 – a Zealand...
Total number of shares and voting rights in Zealand Pharma at January 31, 2024
31. Januar 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 7 / 2024 Total number of shares and voting rights in Zealand Pharma at January 31, 2024 Copenhagen, Denmark, January 31, 2024 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma major shareholder announcement: Van Herk Investments
26. Januar 2024 12:00 ET
|
Zealand Pharma
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no....
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
19. Januar 2024 11:30 ET
|
Zealand Pharma
Company announcement – No. 5 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 19 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL)...
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
17. Januar 2024 10:30 ET
|
Zealand Pharma
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma completes registration of capital increase
12. Januar 2024 05:00 ET
|
Zealand Pharma
Company announcement – No. 3 / 2024 Zealand Pharma completes registration of capital increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES,...
Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC
10. Januar 2024 11:15 ET
|
Zealand Pharma
Company announcement – No. 2 / 2024 Zealand Pharma major shareholder announcement: Avoro Capital Advisors LLC Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
08. Januar 2024 15:45 ET
|
Zealand Pharma
Company announcement – No. 1 / 2024 Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN...